Clinical Report: Standardizing Ocular Toxicity Grading for ADCs

Overview

The introduction of anatomically specific ocular toxicity grading scales aims to enhance the consistency of assessing ocular adverse events associated with antibody-drug conjugates (ADCs). These scales provide explicit recommendations for dose modifications, potentially reducing premature discontinuation of ADC therapies.

Background

Ocular toxicity is a significant concern in patients receiving ADCs, with corneal pseudomicrocysts affecting up to 90% of patients. The previous grading system, the Common Terminology Criteria for Adverse Events (CTCAE), had limitations that led to inconsistent assessments and treatment discontinuations. The new grading scales developed by a multicenter working group aim to address these issues and improve patient management in oncology settings.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Anatomically specific grading scales for ocular toxicity were developed by a consensus group of 23 ophthalmologists and oncologists.
• The new scales separate objective signs from subjective symptoms and provide explicit dose modification recommendations.
• High agreement was observed among panelists, with mean Likert scores of 4.3 to 4.5 for individual domains and 4.6 compared to CTCAE v5.0.
• Implementation of the new grading system in the I-SPY 2 trial did not result in reported irreversible ocular toxicity.
• Despite their effectiveness in clinical trials, real-world application of these scales remains variable among practitioners.
• Ophthalmologists must collaborate closely with medical oncologists to manage ocular adverse events effectively.

Clinical Implications

The standardized grading scales can guide clinicians in assessing ocular toxicity more consistently, potentially improving patient outcomes and reducing unnecessary treatment discontinuations. Ongoing communication between ophthalmologists and oncologists is crucial for managing ocular adverse events in patients receiving ADCs.

Conclusion

The development of standardized ocular toxicity grading scales represents a significant advancement in the management of ocular adverse events associated with ADCs. Their implementation may enhance patient care and treatment adherence in oncology.

References

1. Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting, JAMA Ophthalmology, 2023 -- Standardizing Ocular Toxicity Grading for ADCs
2. Archives of Toxicology — Evaluation of the Draize Test for Severe Eye Injury and Irritation: Significance of In Vivo Endpoints in the Context of UN GHS/EU CLP for Advancing In Vitro Testing Methods
3. Archives of Toxicology — Analysis of Historical In Vivo Data on Severe Eye Damage and Irritation for Chemical Classification: Insights from the Draize Eye Test Reference Database (DRD)
4. Optometric Management — Acquire Medication Adherence Recommendations
5. Retinal Physician — Clinical Trial Update November/December 2023
6. Clinical Trial Update November/December 2023, Retinal Physician
7. Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting | JAMA Ophthalmology | JAMA Network
8. CENTER FOR DRUG EVALUATION AND
9. Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis - PMC